查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096874

生物製藥合約開發與生產組織（CDMO）市場－2026-2032年全球市場預測

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥合約開發和生產組織 (CDMO) 市場將成長至 791 億美元，複合年成長率為 7.43%。

主要市場統計數據
基準年 2025 478.7億美元
預計年份：2026年 513億美元
預測年份 2032 791億美元
複合年成長率 (%) 7.43%

生物製藥合約研發生產機構（CDMO）已成為生物製藥創新者在複雜治療領域尋求速度、品質、法規可靠性和靈活生產能力的關鍵合作夥伴。單株抗體、重組蛋白、疫苗、細胞和基因療法、抗體藥物複合體（ADC）和生物相似藥日益成長的臨床和商業性價值推動了這一需求。與小分子藥物的生產不同，生物製藥CDMO運作需要專門的細胞株開發、上游和下游生物製程、無菌填充和包裝、分析表徵、低溫運輸能力以及嚴格遵守現行藥品生產品質管理規範（cGMP）標準。此外，美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）、世界衛生組織（WHO）以及亞太地區、拉丁美洲、中東和非洲等地區衛生監管機構的監管要求也對該領域產生影響。隨著生物製藥產品線的多樣化，外包策略正日益從單純採購生產能力轉向一體化開發夥伴關係，從而降低技術轉移風險，加強品管體系，並支持從早期製程開發到商業供應的生命週期管理。

生物製藥CDMO產業的變革性變化

隨著療法日益複雜、監管審查日益嚴格以及供應鏈韌性重塑外包決策，生物製藥CDMO產業的結構正在經歷轉型。一次性生物反應器系統、連續生物製程、高通量分析和模組化生產正在推動更快的規模化生產和更具適應性的生產網路，尤其是在多產品生產設施中。贊助商越來越關注端到端能力，包括細胞株開發、製程表徵、製劑、分析測試、原料藥成分（API）生產以及無菌製劑的填充和包裝。個人化療法和小批量療法的興起提升了靈活生產平台的價值，而生物相似藥的出現進一步凸顯了對經濟高效、可重複且符合全球規範的生產方式的需求。地緣政治供應鏈問題以及從疫情中汲取的經驗教訓也在推動雙重採購、區域生產策略和更嚴格的品質協議的實施。同時，在環境期望不斷提高的情況下，生技藥品製造商正在評估用水量、能源效率、樹脂消耗量、廢棄物減少和永續的設施設計，同時又不損害產品完整性或患者安全。

人工智慧對生物製藥CDMO營運的累積影響

人工智慧 (AI) 透過加深對製程的理解、加速決策和加強品管，對生物製藥合約開發和生產 (CDMO) 產生日益顯著的影響。 AI 驅動的工具已被用於細胞株篩檢、培養基最佳化、生物反應器參數建模、偏差檢測、預測性維護和分析數據審查。在製程開發中，機器學習可以幫助識別關鍵程式參數與關鍵品質屬性 (CQA) 之間的關係，並且當與控制良好的數據相結合時，它可以支援品質設計 (QbD) 框架並減輕實驗負擔。在生產營運中，AI 可以支援即時監控、數位化批次記錄、異常檢測和更主動的污染控制策略。對於生物製藥 CDMO 而言，AI 的實際價值取決於檢驗的資料管治、可解釋的模型、網路安全、法規遵循和專家審核。由於生物製藥生產受到嚴格的監管，人工智慧的實施只有在融入受控品質系統、有審計追蹤支持，並且用於補充而不是取代科學和品質保證判斷時，才能最為有效。

生物製藥CDMO市場的關鍵區域洞察

亞太地區在生物製藥CDMO（合約研發生產）活動中扮演著日益重要的角色，這主要得益於不斷擴展的生物製藥產品線、政府對國內生物製藥生產的支持、活性化的臨床試驗以及對生物類似藥、疫苗和先進療法的投資。中國、印度、日本、韓國、新加坡和澳洲各自發揮獨特的優勢，從成本效益高的製程開發和臨床供應，到完善的監管體系和先進的生物製藥生產基礎設施。歐洲的特點是高度協調的法規、嚴格的生物製藥品質標準、成熟的製藥生產技術以及在生物相似藥和先進療法領域的積極參與。德國、英國、法國、義大利和西班牙在歐洲藥品管理局（EMA）和各國監管機構的監管下發揮關鍵作用。北美仍然是生物製藥創新的中心樞紐，這得益於成熟的監管流程、密集的生物技術生態系統、活躍的臨床開發活動以及對高品質商業化生產和填充/包裝服務的需求。儘管大部分此類活動由美國推動，但加拿大也透過其生物製程人才、公共部門對生命科學的投資以及不斷擴大的生技藥品開發能力做出了貢獻。在拉丁美洲，隨著區域醫療保健系統擴大生技藥品的覆蓋範圍並促進本地生產和戰略夥伴關係，生物製藥的重要性日益凸顯。巴西和墨西哥尤其在製藥能力和臨床研究參與方面表現突出。由於疫苗供應、區域生產舉措、技術轉移以及與公共衛生優先事項相關的需求，非洲正成為生物製藥合約研發生產機構（CDMO）的新機遇，並引起廣泛關注。然而，基礎設施、確保熟練勞動力、資金籌措和監管協調仍然是發展的關鍵促進因素。在中東，人們越來越重視醫療保健的自給自足和對生物製藥的投資，特別是透過國家層面的生命科學策略、醫院基礎設施現代化、低溫運輸擴展以及支持未來生物製藥生產夥伴關係的在地化計畫。

團隊對生物製藥CDMO策略的關鍵見解

北約成員國擁有眾多先進的製造地，供應鏈韌性、健全的醫療保健系統、安全的疫苗生產以及生技藥品解決方案在國家衛生安全戰略中日益重要。七國集團（G7）國家在生技藥品創新、監管科學、智慧財產權保護、臨床開發標準和高度複雜的生產製造方面仍然具有影響力，並在高品質的開發和商業供應夥伴關係中發揮關鍵作用。金磚國家為生物製藥合約研發生產力機構（CDMO）提供了多樣化的機遇，這些國家擁有大規模的患者群體、對生物相似藥的需求、科研人才以及政府對國內生產的重視，儘管各國的監管一致性、技術轉移準備情況和基礎設施成熟度有所不同。歐盟（EU）擁有最完善的生物製藥CDMO活動環境之一，其統一的法規結構、完善的GMP標準、健全的藥物安全監測系統和跨境生產網路。東協作為生物製藥製造和開發中心正日益受到關注，其成員國正在加強醫療保健基礎設施、臨床研究能力以及生命科學領域的投資獎勵。新加坡憑藉其先進的基礎設施和成熟的法規環境，為高價值生物製藥企業提供支援；同時，其他東南亞國協也在擴大其在臨床藥物的供應、包裝和區域分銷方面的參與度。海灣合作理事會（GCC）優先考慮醫療本地化、藥品安全和先進醫院系統的發展，這為生物製藥技術轉移、灌裝和包裝夥伴關係、低溫運輸物流以及監管合規能力建設創造了機會。

影響生物製藥CDMO成長重點的主要國家趨勢

中國正憑藉大規模投資、不斷擴大的臨床研究活動和監管現代化，快速推動生物製藥研發、生物相似藥和生產基礎建設。美國是生物製藥CDMO需求的主要中心，這得益於其豐富的生物技術產品線、成熟的法律規範體系、強大的風險投資和機構投資者資金籌措環境，以及眾多需要研發、生產、分析和灌裝/包裝支持的臨床階段生物製藥公司。日本維持著高標準的監管和品質規範，並充分發揮其在創新生物製藥、精準醫療和卓越製造能力方面的優勢。印度以其具有成本競爭力的生物製藥研發、生物相似藥生產、疫苗和高素質的科研人才而聞名，這得益於其在全球製藥生產中長期扮演的角色。德國擁有卓越的工程技術、強大的生物製程能力和先進的製藥製造技術，而英國則在生物製藥創新、細胞和基因治療研發、臨床研究和監管靈活性方面繼續發揮重要作用。澳洲受惠於強大的臨床試驗能力、研究機構以及支持早期研發的環境。法國透過研究基礎設施、疫苗專業知識和醫療創新計畫支持生物製藥產業，而韓國憑藉著先進的基礎設施、技術專長和政府主導的生命科學發展，正在崛起成為重要的生物製藥和生物相似藥生產中心。義大利透過無菌生產、藥品生產技術和契約製造經驗做出貢獻，而加拿大則透過生物製造系統、疫苗生產能力和對生命科學基礎設施的公共投資來加強生物製藥生態系統。俄羅斯擁有科學基礎和國內製藥目標，但地緣政治和監管的限制影響國際合作。巴西仍然是拉丁美洲主要的生物製藥市場，這得益於公共衛生需求、生物相似藥的普及以及國內生產的意願。另一方面，墨西哥則利用接近性北美供應鏈的地理優勢、藥品生產經驗以及該地區對醫療保健產品生產日益成長的興趣。西班牙在生物製藥開發、臨床研究和先進治療領域日益突出，這得益於其強大的醫院網路和與歐洲法規的接軌。

為生物製藥CDMO產業的領導者提供的實用建議

產業領導者應優先考慮整合生物製藥CDMO夥伴關係，這種合作夥伴關係應涵蓋技術能力、法規遵循經驗、品質文化和生命週期支持，而非僅根據現有產能選擇供應商。申辦方必須對GMP記錄、污染控制策略、分析能力、資料完整性系統、技術轉移流程、灌裝和包裝系統進行嚴格的實質審查。建立雙源或區域供應策略可以提高關鍵生物製藥的韌性，尤其是在低溫運輸物流、一次性耗材、層析法樹脂或無菌生產環節可能成為瓶頸的情況下。 CDMO應投資於可擴展的一次性平台、高通量製程開發、數位化品管、進階分析以及生物製藥特定營運領域的人才培養。申辦方和生產商都應儘早納入法規策略，尤其是在等效性、製程驗證、萃取物和洗脫液、病毒安全性、有效性測試以及產品特定品質屬性方面。經營團隊還應建立人工智慧管治框架，加強網路安全，並確保數位工具在受監管的環境中得到適當驗證。永續性應作為提高營運效率的目標，同時關注整個生物製藥生產網路中的水、能源、廢棄物和材料管理。

生物製藥CDMO分析的調查方法

本執行摘要採用系統性的二級和一級研究方法編寫，並專注檢驗的產業證據和監管環境。該調查方法包括對公開的監管指南、GMP框架、臨床開發趨勢、生物製造技術應用、科學論文、政府生命科學戰略以及衛生當局和國際組織發布的資訊進行審查。分析檢驗包括交叉參考區域政策趨勢、生物製藥生產需求、外包促進因素、技術趨勢和治療模式開發。此研究框架評估了生物製藥CDMO在細胞株開發、上游工程、下游純化、分析測試、製劑、原料藥生產、無菌填充和包裝、包裝以及供應鏈支持等服務領域的趨勢。透過監管成熟度、基礎設施建設、科技人才、生物製藥研發管線活動、醫療保健政策方向和生產專業知識等定性指標，評估區域、集團和國家的具體情況。此調查方法著重於基於證據的策略解讀，避免不實估計，也不涉及市場規模、市場佔有率和預測。

關於生物製藥CDMO策略未來發展的結論

隨著治療藥物研發管線向日益複雜的模式擴展，生物製藥合約研發生產機構（CDMO）在全球生物製藥價值鏈中變得不可或缺。該領域以整合研發服務、靈活的生產平台、卓越的監管合規性、數位轉型和穩健的供應鏈網路為特徵。人工智慧、一次性技術、先進分析和區域生物製造舉措正在變革生物製藥的研發、規模化生產、測試和交付方式。北美和歐洲持續提供成熟的創新和法規環境，而亞太地區則透過基礎設施擴張、生物相似藥開發和對先進製造的投資而快速發展。拉丁美洲、中東和非洲正在創造與醫療保健可近性、在地化和技術轉移相關的新機會。對於行業相關人員，成功的關鍵在於品質至上的執行、靈活的產能管理、嚴格的監管合規、安全的數據系統以及支持安全、高效、可靠地向全球患者提供生物製藥的夥伴關係。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物製藥合約開發與生產組織（CDMO）市場：依服務類型分類

  • 合約開發服務
    • 細胞株構建
    • 製程開發
    • 分析與發展
  • 契約製造服務
    • 臨床生產
    • 灌裝和精加工服務
    • 包裝和標籤

第8章：生物製藥合約開發與生產組織（CDMO）市場：依產品類型分類

  • 單株抗體（mAbs）
  • 重組蛋白
  • 疫苗
  • 細胞和基因治療
  • 生物相似藥

第9章：生物製藥合約開發與生產組織（CDMO）市場：按表現系統

  • 哺乳動物細胞培養
  • 微生物發酵
  • 昆蟲細胞表現系統
  • 植物來源的表達系統

第10章：生物製藥合約開發與生產組織（CDMO）市場：依業務規模分類

  • 臨床前生產
  • 臨床生產

第11章：生物製藥合約開發與生產組織（CDMO）市場：依治療領域分類

  • 免疫學
  • 感染疾病
  • 神經病學
  • 腫瘤學

第12章：生物製藥合約開發與生產組織（CDMO）市場：依最終用戶分類

  • 生技公司
  • 製藥公司
  • 學術研究機構

第13章：生物製藥合約開發與生產組織（CDMO）市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：生物製藥合約開發與生產組織（CDMO）市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：生物製藥合約開發與生產組織（CDMO）市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Abzena plc
  • AGC Biologics
  • Almac Group
  • Avid Bioservices, Inc.
  • Batavia Biosciences BV
  • BioFactura, Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics, Inc.
  • Emergent BioSolutions Inc.
  • FUJIFILM Biotechnologies
  • Genezen Laboratories, Inc.
  • Goodwin Biotechnology Inc.
  • JSR Life Science
  • Lonza Group AG
  • Northway Biotechpharma UAB
  • Oxford Biomedica plc
  • Porton Biopharma Limited
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics（Cayman）Inc.
Product Code: MRR-957C47F9527F

The Biologics Contract Development & Manufacturing Organization Market is projected to grow by USD 79.10 billion at a CAGR of 7.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.87 billion
Estimated Year [2026] USD 51.30 billion
Forecast Year [2032] USD 79.10 billion
CAGR (%) 7.43%

Biologics contract development and manufacturing organizations have become critical partners for biopharmaceutical innovators seeking speed, quality, regulatory reliability, and flexible capacity across complex therapeutic modalities. Demand is being shaped by the growing clinical and commercial relevance of monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, antibody-drug conjugates, and biosimilars. Unlike small-molecule manufacturing, biologics CDMO operations require specialized cell line development, upstream and downstream bioprocessing, aseptic fill-finish, analytical characterization, cold-chain readiness, and strict compliance with current good manufacturing practice standards. The sector is also influenced by regulatory expectations from agencies such as the U.S. Food and Drug Administration, European Medicines Agency, World Health Organization, and national health authorities across Asia-Pacific, Latin America, the Middle East, and Africa. As biologics pipelines diversify, outsourcing strategies are increasingly moving beyond capacity buying toward integrated development partnerships that reduce technology-transfer risk, strengthen quality systems, and support lifecycle management from early process development through commercial supply.

Transformative Shifts in the Biologics CDMO Landscape

The biologics CDMO landscape is undergoing structural transformation as therapeutic complexity, regulatory scrutiny, and supply-chain resilience reshape outsourcing decisions. Single-use bioreactor systems, continuous bioprocessing, high-throughput analytics, and modular manufacturing are enabling faster scale-up and more adaptable production networks, particularly for multiproduct facilities. Sponsors are placing greater emphasis on end-to-end capabilities, including cell line development, process characterization, formulation, analytical testing, drug substance manufacturing, and sterile drug product fill-finish. The rise of personalized and small-batch therapies is increasing the value of flexible manufacturing platforms, while biosimilars are intensifying the need for cost-efficient, reproducible, and globally compliant production. Geopolitical supply-chain concerns and pandemic-era lessons have also encouraged dual sourcing, regional manufacturing strategies, and stronger quality agreements. At the same time, environmental expectations are prompting biologics manufacturers to evaluate water use, energy efficiency, resin consumption, waste reduction, and sustainable facility design without compromising product integrity or patient safety.

Cumulative Impact of Artificial Intelligence on Biologics CDMO Operations

Artificial intelligence is increasingly influencing biologics contract development and manufacturing by improving process understanding, accelerating decision-making, and strengthening quality oversight. AI-enabled tools are being applied in cell line screening, media optimization, bioreactor parameter modeling, deviation detection, predictive maintenance, and analytical data review. In process development, machine learning can help identify relationships between critical process parameters and critical quality attributes, supporting quality-by-design frameworks and reducing experimental burden when paired with well-curated data. In manufacturing operations, AI can support real-time monitoring, digital batch records, anomaly detection, and more proactive contamination-control strategies. For biologics CDMOs, the practical value of AI depends on validated data governance, explainable models, cybersecurity, regulatory alignment, and human expert review. Because biologics manufacturing is highly regulated, AI adoption is most effective when embedded into controlled quality systems, supported by audit trails, and used to augment rather than replace scientific and quality assurance judgment.

Key Regional Insights Across Biologics CDMO Markets

Asia-Pacific is becoming increasingly important in biologics CDMO activity due to expanding biopharmaceutical pipelines, government support for domestic biomanufacturing, growing clinical trial activity, and investments in biosimilars, vaccines, and advanced therapies. China, India, Japan, South Korea, Singapore, and Australia each contribute distinct strengths, ranging from cost-efficient process development and clinical supply to sophisticated regulatory systems and advanced biologics manufacturing infrastructure. Europe is characterized by advanced regulatory harmonization, strong biologics quality standards, established pharmaceutical manufacturing expertise, and significant activity in biosimilars and advanced therapies, with Germany, the United Kingdom, France, Italy, and Spain playing important roles under European Medicines Agency and national authority oversight. North America remains a central hub for biologics innovation, supported by mature regulatory pathways, a dense biotechnology ecosystem, strong clinical development activity, and demand for high-quality commercial manufacturing and fill-finish services. The United States anchors much of this activity, while Canada contributes through bioprocessing talent, public-sector life sciences investment, and growing biologics development capabilities. Latin America is gaining relevance as regional healthcare systems expand biologics access and encourage localized production or strategic partnerships, with Brazil and Mexico standing out due to pharmaceutical manufacturing capacity and clinical research participation. Africa remains an emerging biologics CDMO opportunity, with demand linked to vaccine access, regional manufacturing initiatives, technology transfer, and public health priorities, though infrastructure, skilled workforce availability, financing, and regulatory harmonization remain critical development factors. The Middle East is increasingly focused on healthcare self-sufficiency and biopharmaceutical investment, particularly through national life sciences strategies, hospital infrastructure modernization, cold-chain expansion, and localization programs that support future biologics manufacturing partnerships.

Key Group Insights for Biologics CDMO Strategy

NATO countries include many advanced biomanufacturing jurisdictions where supply-chain resilience, medical preparedness, secure production of vaccines, and biologic countermeasures are increasingly relevant to national health security strategies. G7 countries remain influential in biologics innovation, regulatory science, intellectual property protection, clinical development standards, and high-complexity manufacturing, making them important for premium development and commercial supply partnerships. BRICS economies represent diverse biologics CDMO opportunities, combining large patient populations, biosimilar demand, scientific talent, and government interest in domestic production, although regulatory consistency, technology-transfer readiness, and infrastructure maturity vary by country. The European Union provides one of the most structured environments for biologics CDMO activity due to harmonized regulatory frameworks, established GMP expectations, strong pharmacovigilance systems, and cross-border manufacturing networks. ASEAN is gaining attention as a biologics manufacturing and development corridor because member economies are strengthening healthcare infrastructure, clinical research capabilities, and investment incentives for life sciences; Singapore supports high-value biopharmaceutical operations through advanced infrastructure and regulatory maturity, while other ASEAN economies are increasingly involved in clinical supply, packaging, and regional distribution. The GCC is prioritizing healthcare localization, pharmaceutical security, and advanced hospital systems, creating opportunities for biologics technology transfer, fill-finish partnerships, cold-chain logistics, and regulatory capability building.

Key Country Insights Shaping Biologics CDMO Growth Priorities

China is rapidly advancing biologics development, biosimilars, and manufacturing infrastructure, supported by large-scale investment, expanding clinical research activity, and regulatory modernization. The United States is a leading center for biologics CDMO demand due to its extensive biotechnology pipeline, mature regulatory oversight, strong venture and institutional funding environment, and large base of clinical-stage biologics developers requiring development, manufacturing, analytical, and fill-finish support. Japan maintains high regulatory and quality standards with strengths in innovative biologics, precision medicine, and manufacturing excellence. India is recognized for cost-competitive biopharmaceutical development, biosimilar manufacturing, vaccines, and skilled scientific talent, supported by a long-standing role in global pharmaceutical production. Germany combines engineering excellence, bioprocessing strength, and advanced pharmaceutical manufacturing, while the United Kingdom continues to play a key role in biologics innovation, cell and gene therapy development, clinical research, and regulatory agility. Australia benefits from strong clinical trial capabilities, research institutions, and supportive early-phase development conditions. France supports biologics through research infrastructure, vaccine expertise, and healthcare innovation programs, while South Korea has emerged as a major biologics manufacturing and biosimilar center, supported by advanced infrastructure, technical expertise, and government-backed life sciences development. Italy contributes through sterile manufacturing, pharmaceutical production know-how, and contract manufacturing experience, and Canada is strengthening its biologics ecosystem through public investment in biomanufacturing preparedness, vaccine capacity, and life sciences infrastructure. Russia has scientific capacity and domestic pharmaceutical objectives, although geopolitical and regulatory constraints affect international collaboration. Brazil remains a major Latin American biologics market supported by public health demand, biosimilar adoption, and local manufacturing ambitions, while Mexico offers proximity to North American supply chains, pharmaceutical manufacturing experience, and growing interest in regional healthcare production. Spain is increasingly visible in biopharmaceutical development, clinical research, and advanced therapy initiatives, supported by a strong hospital network and European regulatory alignment.

Actionable Recommendations for Biologics CDMO Industry Leaders

Industry leaders should prioritize integrated biologics CDMO partnerships that align technical capability, regulatory experience, quality culture, and lifecycle support rather than selecting suppliers based only on available capacity. Sponsors should conduct rigorous due diligence on GMP history, contamination-control strategies, analytical capabilities, data integrity systems, technology-transfer processes, and fill-finish readiness. Building dual-source or regionalized supply strategies can improve resilience for critical biologics, especially where cold-chain logistics, single-use consumables, chromatography resins, or sterile manufacturing slots may create bottlenecks. CDMOs should invest in scalable single-use platforms, high-throughput process development, digital quality management, advanced analytics, and workforce training in biologics-specific operations. Both sponsors and manufacturers should embed regulatory strategy early, particularly for comparability, process validation, extractables and leachables, viral safety, potency assays, and product-specific quality attributes. Leaders should also establish AI governance frameworks, strengthen cybersecurity, and ensure digital tools are validated for regulated environments. Sustainability should be treated as an operational efficiency objective, with attention to water, energy, waste, and materials management across biologics production networks.

Research Methodology for Biologics CDMO Analysis

This executive summary is developed using a structured secondary and primary research approach focused on verified industry evidence and regulatory context. The methodology incorporates review of public regulatory guidance, GMP frameworks, clinical development trends, biomanufacturing technology adoption, scientific publications, government life sciences strategies, and publicly available information from health authorities and international organizations. Analytical validation includes cross-referencing regional policy signals, biologics manufacturing requirements, outsourcing drivers, technology trends, and therapeutic modality developments. The research framework evaluates biologics CDMO dynamics across service areas such as cell line development, upstream processing, downstream purification, analytical testing, formulation, drug substance production, aseptic fill-finish, packaging, and supply-chain support. Regional, group, and country insights are assessed through qualitative indicators including regulatory maturity, infrastructure readiness, scientific workforce, biopharmaceutical pipeline activity, healthcare policy direction, and manufacturing specialization. The methodology avoids unsupported estimates and excludes market sizing, market share, and forecasting to maintain focus on evidence-backed strategic interpretation.

Conclusion on the Future of Biologics CDMO Strategy

Biologics contract development and manufacturing organizations are becoming indispensable to the global biopharmaceutical value chain as therapeutic pipelines expand into increasingly complex modalities. The sector's direction is defined by integrated development services, flexible manufacturing platforms, regulatory excellence, digital transformation, and resilient supply networks. Artificial intelligence, single-use technologies, advanced analytics, and regional biomanufacturing initiatives are changing how biologics are developed, scaled, tested, and supplied. North America and Europe continue to provide mature innovation and regulatory environments, while Asia-Pacific is accelerating through infrastructure expansion, biosimilar development, and advanced manufacturing investment. Latin America, the Middle East, and Africa present emerging opportunities tied to healthcare access, localization, and technology transfer. For industry participants, success will depend on quality-first execution, adaptable capacity, strong regulatory alignment, secure data systems, and collaborative partnerships that support safe, efficient, and reliable delivery of biologic medicines to patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Contract Development & Manufacturing Organization Market, by Service Type

  • 7.1. Introduction
  • 7.2. Contract Development Services
    • 7.2.1. Cell Line Development
    • 7.2.2. Process Development
    • 7.2.3. Analytical Development
  • 7.3. Contract Manufacturing Services
    • 7.3.1. Clinical Manufacturing
    • 7.3.2. Fill-Finish Services
    • 7.3.3. Packaging & Labeling

8. Biologics Contract Development & Manufacturing Organization Market, by Product Type

  • 8.1. Introduction
  • 8.2. Monoclonal Antibodies (mAbs)
  • 8.3. Recombinant Proteins
  • 8.4. Vaccines
  • 8.5. Cell & Gene Therapies
  • 8.6. Biosimilars

9. Biologics Contract Development & Manufacturing Organization Market, by Expression System

  • 9.1. Introduction
  • 9.2. Mammalian Cell Culture
  • 9.3. Microbial Fermentation
  • 9.4. Insect Cell Expression Systems
  • 9.5. Plant-Based Expression Systems

10. Biologics Contract Development & Manufacturing Organization Market, by Scale of Operation

  • 10.1. Introduction
  • 10.2. Preclinical Manufacturing
  • 10.3. Cinical Manufacturing

11. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category

  • 11.1. Introduction
  • 11.2. Immunology
  • 11.3. Infectious Disease
  • 11.4. Neurology
  • 11.5. Oncology

12. Biologics Contract Development & Manufacturing Organization Market, by End User

  • 12.1. Introduction
  • 12.2. Biotechnology Companies
  • 12.3. Pharmaceutical Companies
  • 12.4. Academic & Research Institutes

13. Biologics Contract Development & Manufacturing Organization Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Biologics Contract Development & Manufacturing Organization Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Biologics Contract Development & Manufacturing Organization Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Abzena plc
  • 17.3. AGC Biologics
  • 17.4. Almac Group
  • 17.5. Avid Bioservices, Inc.
  • 17.6. Batavia Biosciences B.V.
  • 17.7. BioFactura, Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Catalent, Inc.
  • 17.10. Charles River Laboratories International, Inc.
  • 17.11. Cytovance Biologics, Inc.
  • 17.12. Emergent BioSolutions Inc.
  • 17.13. FUJIFILM Biotechnologies
  • 17.14. Genezen Laboratories, Inc.
  • 17.15. Goodwin Biotechnology Inc.
  • 17.16. JSR Life Science
  • 17.17. Lonza Group AG
  • 17.18. Northway Biotechpharma UAB
  • 17.19. Oxford Biomedica plc
  • 17.20. Porton Biopharma Limited
  • 17.21. Recipharm AB
  • 17.22. Rentschler Biopharma SE
  • 17.23. Samsung Biologics Co., Ltd.
  • 17.24. Siegfried Holding AG
  • 17.25. Thermo Fisher Scientific Inc.
  • 17.26. WuXi Biologics (Cayman) Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FILL-FINISH SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FILL-FINISH SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FILL-FINISH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONOCLONAL ANTIBODIES (MABS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONOCLONAL ANTIBODIES (MABS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONOCLONAL ANTIBODIES (MABS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICROBIAL FERMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICROBIAL FERMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICROBIAL FERMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSECT CELL EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSECT CELL EXPRESSION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSECT CELL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PLANT-BASED EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLANT-BASED EXPRESSION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PLANT-BASED EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRECLINICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CINICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CINICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CINICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 160. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 258. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 260. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SCALE OF O